ABL Diagnostics wins court approval to take over TEXCELL activities

ABL Diagnostics has been chosen by the Évry commercial court to acquire TEXCELL’s assets and operations, keeping the Genopole site in Évry-Courcouronnes open and retaining 29 employees. The move expands ABL Diagnostics’ footprint in virology, biosafety and infectious-disease testing while adding scientific capabilities linked to the Institut Pasteur ecosystem.

Why it matters: - The takeover strengthens ABL Diagnostics in life sciences and infectious-disease testing at a time when the company is trying to expand beyond its core molecular diagnostics business. - The deal preserves scientific capabilities and jobs at the Genopole site in Évry-Courcouronnes. - ABL Diagnostics gains complementary expertise in virology, biosafety, biological control and cell culture that can support future research and commercial development.

What happened: - The Tribunal de commerce d'Évry selected ABL Diagnostics to take over TEXCELL’s assets and activities. - The transaction covers TEXCELL’s strategic assets, transferred commercial contracts and operations at the Genopole d'Évry-Courcouronnes. - ABL Diagnostics said the acquisition fits its industrial plan to ensure business continuity and build synergies in molecular diagnostics, virology and infectious diseases. - The company said it will later disclose how the acquisition will be integrated into its 2026 strategic roadmap.

The details: - The takeover includes 29 employees, made up of 23 permanent workers and 6 apprentices. - ABL Diagnostics will also assume acquired employee entitlements for 91,829.24 euros, subject to final adjustment. - TEXCELL traces its scientific roots to the Institut Pasteur ecosystem and has recognized expertise in viral safety, biosafety, genomic analysis, immune monitoring and services for biotech and innovative therapies. - Publicly available information shows TEXCELL France generated about 5.4 million euros in revenue in 2024, down from 6.2 million euros in 2023 and 7.5 million euros in 2022. - The overall economic value of the project is about 2.9 million euros. - That figure includes a 225,000-euro asset sale price, split between 165,000 euros for intangible assets and 60,000 euros for tangible assets. - The project also includes a 30,000-euro purchase of inventory, about 100,000 euros to rebuild security deposits, and 531,792.74 euros in assumed equipment lease contracts and upcoming installments. - ABL Diagnostics is planning 930,000 euros in industrial and technology investment and 1 million euros in additional working capital. - The acquisition is being financed with the group’s available financial resources. - The accepted offer’s terms are included in documents filed with the Évry commercial court.

Between the lines: - The move extends ABL Diagnostics’ scientific strategy around the Institut Pasteur, following its recent initiative with Institut Pasteur de Paris on HPV RNA-Seq genotyping. - TEXCELL’s expertise aligns with ABL Diagnostics platforms UltraGene, DeepChek® and Nadis®, which should make integration easier on the technical side. - The Genopole base gives ABL Diagnostics a stronger operational presence near a recognized French biotech cluster. - Management also appears to be buying optionality: the acquired viral banks, cell lines and biosafety infrastructure could support new tools for biomedical research, quality control and molecular diagnostics. - Dr. Chalom Sayada said the deal brings recognized scientific expertise, qualified teams, an established international brand and complementary biological assets. - Sayada also said ABL Diagnostics plans to invest in automation, infrastructure upgrades, team expansion and scientific development.

What's next: - ABL Diagnostics will complete the legal and administrative steps needed to finalize the takeover. - The company expects to recruit about five additional employees to support TEXCELL’s activities. - ABL Diagnostics said it will later provide more detail on integration plans and the deal’s impact on its 2026 objectives.

The bottom line: - ABL Diagnostics is using a court-approved acquisition to deepen its position in virology and infectious diseases while preserving a Genopole site, retaining staff and adding new scientific assets.